Dear Nishant,
Your target is to grow 3 to 4 stocks 3x to 4x but please elaborate over what timeframe - 4, 6, 8, 10 years?
You are aware that a concentrated portfolio has its pros and cons.
A 70% allocation to two pharma stocks run the risk of sectoral headwinds in case an FDA debacle.
I dont know if you are the type who cuts his losses readily and reallocates or someone who has ownership bias and tends to stick through the tough times - this is another aspect you should consider prior to making such large allocations.
Eg. the well regarded IPCA which will likely recover and get its act together SOMETIME, however only time will tell how soon the rebound comes. In the meanwhile anyone invested in IPCA over the past 30+ months has not made any gains today. Opportunity cost of having nil returns on this well regarded story over 2.5 years must be considered.
If you love pharma as a sector for wealth creation- consider this - how about mentally mapping Pharma as one basket where you allocate upto total 40% - you can buy a basket of 4 or more good growth prospect stocks that appeal to you (e.g. Granules, Alembic, Torrent, Shilpa, Syngene) and dilute your risk. Statistically this will work to your advantage and protect your downside.
However, if you must allocate to not more than 4 stocks and 2 of those stocks have to be pharma - then I would request you to sincerely consider not allocating over 20% to each pharma story, so that your portfolio performance is not impacted in case of some misfortune.
Regarding other allocations, you should look for worthy allocation ideas. Certainly Canfin and Gruh are worthy bets, as are some other NBFC stories which offer good margin of safety and robust earning growth possibilities.
Indo Count is a story that I personally like - its high R.O.E., premiumisation and growth prospects. This is one prospect I consider a potential steady compounder at 18 % plus return. (I am more than happy with such return). Navin Fluorine is another high growth prospect you could research and consider.
Wish you all luck with the concentrated strategy.
Best regards,
Aniket.
Disc: I am invested in all names mentioned above. Not a buy or sell recommendation do your own diligence.